Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 623 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Cancer Research UK’s Race for Life celebrates its 30th year by... April 24, 2023 Countdown to 100,000 OncoLife Survivorship Care Plans: How it all started February 19, 2021 EMA Recommends Extension of Therapeutic Indications for Irinotecan Hydrochloride Trihydrate April 3, 2024 The Healing Power of Being Outdoors for People With Cancer July 23, 2020 Load more HOT NEWS Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death... Data from a Large Cohort of Patients with mRCC Demonstrate the... Immunotherapy before Surgery Appears Effective for Some with Melanoma Lack of Evidence for the Use of Telemedicine in the Prevention...
